Wright Christopher I 4

Accession 0001127602-24-017732

CIK 0001520262other

Filed

Jun 3, 8:00 PM ET

Accepted

Jun 4, 5:05 PM ET

Size

27.8 KB

Accession

0001127602-24-017732

Form 4

Period: 2024-05-31

Director

Transactions

Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$30.86/sh+231$7,129→ 11,785 total
Exercise: $30.86Exp: 2032-07-07→ Ordinary Shares (231 underlying)
Other
Restricted Stock Unit Award
2023-11-17+119→ 6,104 total
From: 2024-06-29→ Ordinary Shares (119 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$28.40/sh+14$398→ 728 total
Exercise: $28.40Exp: 2032-06-08→ Ordinary Shares (14 underlying)
Other
Restricted Stock Unit Award
2023-11-17+129→ 6,602 total
→ Ordinary Shares (129 underlying)
Award
Restricted Stock Unit Award
2024-05-31+8,013→ 8,013 total
From: 2025-05-31→ Ordinary Shares (8,013 underlying)
Award
Non Qualified Stock Option (Right to Buy)
2024-05-31+17,492→ 17,492 total
Exercise: $23.40From: 2025-05-31Exp: 2034-05-31→ Ordinary Shares (17,492 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$30.72/sh+254$7,803→ 12,986 total
Exercise: $30.72From: 2024-06-29Exp: 2033-06-29→ Ordinary Shares (254 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$28.40/sh+355$10,082→ 18,128 total
Exercise: $28.40Exp: 2032-06-08→ Ordinary Shares (355 underlying)

Footnotes (9)

[F1]Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
[F2]These options are fully vested in accordance with their terms.
[F3]Shares subject to the stock option award vest in three equal annual installments commencing on 6/8/2023.
[F4]Each restricted stock unit represents a contingent right to receive one ordinary share.
[F5]Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023.
[F6]Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
[F7]Shares subject to the restricted stock unit award vest in full on 6/29/2024.
[F8]Shares subject to the restricted stock unit award vest in full on 5/31/2025.
[F9]Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.

Documents

2 files

Alkermes plc.

CIK 0001520262

Entity typeother